The reproductive tract

Seminars in Nuclear Medicine

Volumn 34, Issue 4, 2004, Pages 262-273

  Jadvar, Hossein ^a   Conti, Peter S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID C 11; ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CHOLINE C 11; CHORIONIC GONADOTROPIN; CISPLATIN; DIACETYL BIS N(4) METHYLTHIOSEMICARBOZONE CU 60; FLUORODEOXYGLUCOSE; GLUCOSE TRANSPORTER 1; METHIONINE C 11; RADIOPHARMACEUTICAL AGENT; TRACER; TYROSINE C 11; UNCLASSIFIED DRUG;

ABDOMINAL HYSTERECTOMY; ADENOCARCINOMA; BEAM THERAPY; BRACHYTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DRUG UPTAKE; ENDOMETRIUM CARCINOMA; ENDOMETRIUM TUMOR; GENITAL TRACT CANCER; HUMAN; INTERMETHOD COMPARISON; LAPAROSCOPY; LAPAROTOMY; LYMPH NODE METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; OVARY CARCINOMA; PENIS CANCER; POSITRON EMISSION TOMOGRAPHY; REVIEW; SALPINGOOOPHORECTOMY; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; TESTIS CANCER; TUMOR VOLUME; UTERINE CERVIX CANCER; UTERINE TUBE TUMOR; UTERUS CANCER; VAGINA CANCER; VULVA CANCER; VULVECTOMY;

EID: 5544231288     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2004.06.003     Document Type: Article

References (137)

1. National Cancer Institute Surveillance, Epidemiology, and End Results (NCI-SEER) Program Available at http://seer.cancer.gov 2003 accessed July 8, 2004
2. S.B. Gusberg, C.D. Runowicz Gynecologic Cancers A.I. Holleb D.J. Fink G.P. Murphy Clinical Oncology 1991 American Cancer Society Atlanta, GA 481 497
3. M. Follen, C.F. Levenback, R.B. Iyer Imaging in cervical cancer Cancer 98 2003 2028 2038
4. I.G. Kerr, M.F. Manji, J. Powe Positron emission tomography for the evaluation of metastases in patients with carcinoma of the cervix A retrospective review Gynecol Oncol 81 2001 477 480
5. G. Kuhnel, L.C. Horn, U. Fischer 18F-FDG positron emission tomography in cervical carcinoma preliminary findings Zentralbl Gynakol 123 2001 229 235
6. P.G. Rose, L.P. Adler, M. Rodriguez Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging A surgicopathologic study J Clin Oncol 17 1999 41 45
7. Y. Sugawara, A. Eisbruch, S. Kosuda Evaluation of FDG PET in patients with cervical cancer J Nucl Med 40 1999 1125 1131
8. Y. Shimotsu, Y. Ishida, K. Fukuchi Fluorine-18-fluorodeoxyglucose PET identification of cardiac metastasis arising from uterine cervical carcinoma J Nucl Med 39 1998 2084 2087
9. A. Aizer-Dannon, A. Bar-Am, I.G. Ron Fused functional-anatomic images of metastatic cancer of cervix obtained by a combined gamma camera and X-ray tube hybrid system with an illustrative case and review of the (18)F- fluorodeoxyglucose literature Gynecol Oncol 90 2003 453 457
10. T.C. Yen, L.C. See, C.H. Lai 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression J Nucl Med 45 2004 22 29
11. W.C. Lin, Y.C. Hung, L.S. Yeh Usefulness of (18)F-fluorodeoxyglucose positron emission tomography to detect para-aortic lymph nodal metastasis in advanced cervical cancer with negative computed tomography findings Gynecol Oncol 89 2003 73 76
12. L.S. Yeh, Y.C. Hung, Y.Y. Shen Detecting para-aortic lymph nodal metastasis by positron emission tomography of 18F-fluorodeoxyglucose in advanced cervical cancer with negative magnetic resonance imaging findings Oncol Rep 9 2002 1289 1292
13. K. Narayan, R.J. Hicks, T. Jobling A comparison of MRI and PET scanning in surgically staged loco-regionally advanced cervical cancer potential impact on treatment Int J Gynecol cancer 11 2001 263 271
14. M.J. Reinhardt, C. Ehritt-Braun, D. Vogelgesang Metastatic lymph nodes in patients with cervical cancer detection with MR imaging and FDG PET Radiology 218 2001 776 782
15. P.W. Grigsby, B.A. Siegel, F. Dehdashti Lymph node staging by positron emission tomography in patients with carcinoma of the cervix J Clin Oncol 19 2001 3745 3749
16. B.N. Tran, P.W. Grigsby, F. Dehdashti Occult supraclavicular lymph node metastasis identified by FDG-PET in patients with carcinoma of the uterine cervix Gynecol Oncol 90 2003 572 576
17. N. Umesaki, T. Tanaka, M. Miyama early and evaluation of therapy in postoperative recurrent cervical cancers by positron emission tomography Oncol Rep 7 2000 53 56
18. N. Umesaki, T. Tanaka, M. Miyama The role of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG-PET) in the diagnosis of recurrence and lymph node metastasis of cervical cancer Oncol Rep 7 2000 1261 1264
19. L.J. Havrilesky, T.Z. Wong, A.A. Secord The role of PET scanning in the detection of recurrent cervical cancer Gynecol Oncol 90 2003 186 190
20. D.H. Park, K.H. Kim, S.Y. Park Diagnosis of recurrent uterine cervical cancer computed tomography versus positron emission tomography Korean J Radiol 1 2000 51 55
21. S.S. Sun, T.C. Chen, R.F. Yen Value of whole body 18F-fluoro-deoxyglucose positron emission tomography in the evaluation of recurrent cervical cancer Anticancer Res 21 2001 2957 2961
22. H. Jadvar, P.S. Conti FDG PET in the evaluation of women with cervical carcinoma Radiology 221 2001 386
23. S.Y. Ryu, M.H. Kim, S.C. Choi Detection of early recurrence with 18F-FDG PET in patients with cervical cancer J Nucl Med 44 2003 347 352
24. T.C. Yen, K.K. Ng, S.Y. Ma Value of dual-phase 2-fluoro-2-deoxy-d-glucose positron emission tomography in cervical cancer J Clin Oncol 21 2003 3651 3658
25. S.Y. Ma, L.C. See, C.H. Lai Delayed (18)F-FDG PET for detection of paraaortic lymph node metastases in cervical cancer patients J Nucl Med 44 2003 1775 1783
26. D.W. Townsend, T. Beyer A combined PET/CT scanner The path to true image fusion Br J Radiol 75 2002 S24 S30
27. M. Tatsumi, C. Cohade, R. Zellars Initial experience in imaging uterine cervical cancer with FDG PET-CT Direct comparison with PET J Nucl Med 5 suppl 2003 394P
28. T. Beyer, D.W. Townsend, T.M. Blodgett Dual modality PET/CT tomography for clinical oncology Q J Nucl Med 46 2002 24 34
29. T. Belhocine, A. Thille, V. Fridman Contribution of whole-body 18FDG PET imaging in the management of cervical cancer Gynecol Oncol 87 2002 90 97
30. R.S. Malyapa, S. Mutic, D.A. Low Physiologic FDG-PET three-dimensional brachytherapy treatment planning for cervical cancer Int J Radiat Oncol Biol Phys 54 2002 1140 1146
31. J. Dose, G.E. Hemminger, K.H. Bohuslavizki Therapy monitoring using FDG-PET in metastatic cervical cancer Lancet Oncol 1 2000 106
32. Y. Nakamoto, A. Eisbruch, E.D. Achtyes Prognostic value of positron emission tomography using F-18-fluorodeoxyglucose in patients with cervical cancer undergoing radiotherapy Gynecol Oncol 84 2002 289 295
33. T.R. Miller, P.W. Grisby Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy Int J Radiat Oncol Biol Phys 53 2002 353 359
34. A.K. Singh, P.W. Grigsby, F. Dehdashti FDG-PET lymph node staging and survival of patients with FIGO stage IIIb cervical carcinoma Int J Radiat Oncol Biol Phys 56 2003 489 493
35. P.W. Grigsby, B.A. Siegel, F. Dehdashti Posttherapy surveillance monitoring of cervical cancer by FDG-PET Int J Radiat Oncol Biol Phys 55 2003 907 913
36. T.R. Miller, E. Pinkus, F. Dehdashti Improved prognostic value of 18F-FDG PET using a simple visual analysis of tumor characteristics in patients with cervical cancer J Nucl Med 44 2003 192 197
37. F. Dehdashti, P.W. Grigsby, M.A. Mintun Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM relationship to therapeutic response-a preliminary report Int J Radiat Oncol Biol Phys 55 2003 1233 1238
38. T. Belhocine An appraisal of 18F-FDG PET imaging in post-therapy surveillance of uterine cancers clinical evidence and a research proposal Int J Gynecol Cancer 13 2003 228 233
39. M. Lapela, S. Leskinen-Kallio, M. Varpula Imaging of uterine carcinoma by carbon-11-methionine and PET J Nucl Med 35 1994 1618 1623
40. T. Nakahara, H. Fujii, M. Ide F-18 FDG uptake in endometrial cancer Clin Nucl Med 26 2001 82 83
41. S.S. Lentz Endometrial carcinoma diagnosed by positron emission tomography A case report Gynecol Oncol 86 2002 223 224
42. T. Belhocine, C. De Barsy, R. Hustinx Usefulness of (18)F-FDG PET in the post-therapy surveillance of endometrial carcinoma Eur J Nucl Med Mol Imaging 29 2002 1132 1139
43. T. Saga, T. Higashi, T. Ishimori Clinical value of FDG-PET in the follow-up of post-operative patients with endometrial cancer J Nucl Med 5 suppl 2003 385P
44. C.H. Kao FDG uptake in a huge uterine myoma Clin Nucl Med 28 2003 249
45. S. Chander, C.C. Meltzer, B.M. McCook Physiologic uterine uptake of FDG during menstruation demonstrated with serial combined positron emission tomography and computed tomography Clin Nucl Med 27 2002 22 24
46. H. Lerman, U. Metser, D. Grisaru Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients assessment by PET/CT J Nucl Med 45 2004 266 271
47. N. Umesaki, T. Tanaka, M. Miyama Positron emission tomography using 2-[(18)F]fluoro-2-deoxy-D-glucose in the diagnosis of uterine leiomyosarcoma A case report Clin Imaging 25 2001 203 205
48. N. Umesaki, T. Tanaka, M. Miyama Positron emission tomography with (18)F-fluorodeoxyglucose of uterine sarcoma a comparison with magnetic resonance imaging and power Doppler imaging Gynecol Oncol 80 2001 372 377
49. S. Cher, E. Lay Ergun Positron emission tomographic-computed tomographic imaging of a uterine sarcoma Clin Nucl Med 28 2003 443 444
50. R.S. Liu, H.J. Hsieh, Y.J. Chen 18F-FDG and 11C-acetate PET imaging in the post-therapy surveillance of endometrial carcinoma J Nucl Med 5 suppl 2003 396P
51. M. Markman The use of PET scanning in ovarian cancer Gynecol Oncol 85 2002 391
52. K. Koyama, T. Okamura, J. Kawabe Evaluation of 18F-FDG PET with bladder irrigation in patients with uterine and ovarian tumors J Nucl Med 44 2003 353 358
53. S. Fenchel, D. Grab, K. Nuessle Asymptomatic adnexal masses correlation of FDG PET and histopathologic findings Radiology 223 2002 780 788
54. A. Rieber, K. Nussie, I. Stohr Preoperative diagnosis of ovarian tumors with MR imaging Comparison with transvaginal sonography, positron emission tomography, and histologic findings Am J Roentgenol 177 2001 123 129
55. Y. Yoshida, T. Kurokawa, K. Kawahara Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer AmJ Roentgenol 182 2004 227 233
56. W. Schroder, M. Zimmy, C. Rudlowski The role of 18F-fluoro-deoxyglucose positron emission tomography (18F-FDG PET) in diagnosis of ovarian cancer Int J Gynecol Cancer 9 1999 117 122
57. A. Turlakow, H.W. Yeung, A.S. Salmon Peritoneal carcinomatosis role of 18F-FDG PET J Nucl Med 44 2003 1407 1412
58. A. Safaei, J. Meta, S.S. Gambhir Impact of whole body PET imaging with FDG on staging and managing patients with ovarian cancer the referring physician's point of view J Nucl Med 5 suppl 2001 285P
59. M. Picchio, S. Sironi, C. Messa Advanced ovarian carcinoma usefulness of ([(180F]FDG-PET in combination with CT for lesion detection after primary treatment Q J Nucl Med 47 2000 77 84
60. R.E. Bristow, F. Simpkins, H.K. Pannu Positron emission tomography for detecting clinically occult surgically respectable metastatic ovarian cancer Gynecol Oncol 85 2002 196 200
61. O. Drieskens, S. Stroobants, M. Gysen Positron emission tomography with FDG in the detection of peritoneal and retroperitoneal metastases of ovarian cancer Gynecol Obstet Invest 55 2003 130 134
62. O. Ishiko, K. Honda, K. Hirai Diagnosis of metastasis of ovarian clear cell carcinoma to the peritoneum of the abdominal wall by positron emission tomography with (fluorine-18)-2-deoxyglucose Oncol Rep 8 2001 67 69
63. R.A. Kubik-Huch, W. Dorffler, G.K. von Schulthess Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma Eur Radiol 10 2000 761 767
64. M. Zimmy, W. Schroder, S. Wolters 18F-fluorodeoxyglucose PET in ovarian carcinoma methodology and preliminary results Nuklearmedizin 36 1997 228 233
65. H. Jadvar, R. Tatlidil, P.S. Conti FDG-PET in the evaluation of recurrent ovarian cancer J Nucl Med 42 suppl 5 2001 286P
66. S. Ryu, J. Kim, B.g. Kim FDG-PET scan cannot substitute for second look operation in patients with ovarian cancer showing clinical complete response with chemotherapy J Nucl Med 5 suppl 2001 286P
67. M. Manuel, C.H. Holschneider, C.M. Williams Correlation of FDG-PET scans with surgicopathologic findings in ovarian cancers J Nucl Med 5 suppl 2002 29P
68. C.H. Holschneider, M. Manuel, C.M. Williams FDG-PET in ovarian cancer use of the standardized uptake value (SUV) to differentiate physiological bowel cavity from intraperitoneal metastatic tumor J Nucl Med 5 suppl 2002 29P
69. S.M. Cho, H.K. Ha, J.Y. Byaun Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer Am J Roentgenol 179 2002 391 395
70. S. Makhija, N. Howden, R. Edwards Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma A retrospective review Gynecol Oncol 85 2002 53 58
71. C. Cohade, K.A. Mourtziks, H.K. Pannu Direct comparison of PET and PET/CT in the detection of recurrent ovarian cancer J Nucl Med 5 suppl 2003 129P
72. T.M. Blodgett, C.C. Meltzer, D.W. Townsend PET/CT in re-staging patients with ovarian carcinoma J Nucl Med 5 suppl 2002 310P
73. O. Israel, Z. Keidar, R. Bar-Shalom Hybrid PET/CT imaging with FDG in management of patients with gynecologic malignancies J Nucl Med 5 suppl 2003 129P
74. P.G. Rose, P. Faulhaber, F. Miraldi Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma correlation with second-look laparotomy Gynecol Oncol 82 2001 17 21
75. K.F. Hubner, T.W. McDonald, G.T. Smith Detection of recurrent ovarian cancer by PET using FDG Clin Positron Imaging 2 1999 346
76. K.F. Hubner, T.W. McDonald, J.G. Niethammer Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[18F]deoxyglucose (2-[18F]FDG) Gynecol Oncol 51 1993 197 204
77. B.Y. Karlan, R. Hawkins, C. Hoh Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma Gynecol Oncol 51 1993 175 181
78. M. Zimmy, W. Siggelkow, W. Schroder 2-[Fluorine-18]-fluoro-2-deoxy-d- glucose positron emission tomography in the diagnosis of recurrent ovarian cancer Gynecol Oncol 83 2001 310 315
79. A. Maldonado, F. Sancho, R. Perez-Carrion Value of FDG-PET in the therapeutic management of recurrent ovarian cancer. Experience in 31 patients Clin Positron Imaging 2 1999 321
80. G.T. Smith, K.F. Hubner, T. McDonald Avoiding second-look surgery and reducing costs in managing patients with ovarian cancer by applying F-18-FDG PET Clin Positron Imaging 1 1998 263
81. G.T. Smith, K.F. Hubner, T. McDonald Cost analysis of FDG PET for managing patients with ovarian cancer Clin Positron Imaging 2 1999 63 70
82. M.J. Garcia Velloso, F. Boan Garcia J, L.M. Villar Luque F-18-FDG positron emission tomography in the diagnosis of ovarian recurrence. Comparison with CT scan and CA-125 Rev Esp Med Nucl 22 2003 217 223
83. N. Mahy, I. Mathieu, B. Willemart The place of PET-FDG in the diagnosis of recurrent ovarian cancer J Nucl Med 5 suppl 2003 130P
84. W.C. Chang, Y.C. Hung, C.H. Kao Usefulness of whole body positron emission tomography (PET) with 18F-fluoro-2-deoxyglucose (FDG) to detect recurrent ovarian cancer based on asymptomatically elevated serum levels of tumor marker Neoplasma 49 2002 329 333
85. T. Torizuka, S. Nobezawa, T. Kanno Ovarian cancer recurrence role of whole-body positron emission tomography using 2-[fluoro-18]-fluoro-2-deoxy-D- glucose Eur J Nucl Med Mol Imaging 29 2002 797 803
86. R.F. Yen, S.S. Sun, Y.Y. Shen Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection recurrent ovarian cancer Anticancer Res 21 2001 3691 3694
87. T. Kurokawa, Y. Yoshida, K. Kawahara Whole-body PET with FDG is useful for following up an ovarian cancer patient with only rising CA-125 levels within the normal range Ann Nucl Med 16 2002 491 493
88. C.C. Yuan, R.S. Liu, P.H. Wang Whole-body PET with (fluorine-18)-2- deoxyglucose for detecting recurrent ovarian carcinoma. Initial Report J Reprod Med 44 1999 775 778
89. M.J. Casey, N.C. Gupta, C.K. Muths Experience with positron emission tomography (PET) scans in patients with ovarian cancer Gynecol Oncol 53 1994 331 338
90. Y. Nakamoto, T. Saga, T. Ishimori Clinical value of positron emission tomography with FDG for recurrent ovarian cancer AJR Am J Roentgenol 176 2001 1449 1454
91. S. Dadparvar, C. Chotipanich, L. Guan 18FDG-PET imaging in detection of recurrent ovarian carcinoma J Nucl Med 5 suppl 2003 131P
92. H.K. Pannu, R.E. Bristow, C. Cohade PET-CT in recurrent ovarian cancer Initial observations Radiographics 24 2004 209 223
93. R.E. Bristow, M.G. del Carmen, H.K. Pannu Clinically occult recurrent ovarian cancer patient selection for secondary cytoreductive surgery using combined PET/CT Gynecol Oncol 90 2003 519 528
94. T. Torizuka, T. Kanno, M. Futatsubashi Imaging of gynecologic tumors Comparison of (11)C-choline PET with (18)F-FDG PET J Nucl Med 44 2003 1051 1056
95. M. Lapela, S. Lekinen-Kallio, M. Varpula Metabolic imaging of ovarian tumors with carbon-11-methionine a PET study J Nucl Med 36 1995 2196 2200
96. B.Y. Karlan, C. Hoh, N. Tse Whole-body positron emission tomography with (fluorine-18)-2-deoxyglucose can detect metastatic carcinoma of the fallopian tube Gynecol Oncol 49 1993 383 388
97. P.V. Patel, C. Cohade, B.B. Chin PET-CT localizes previously undetectable metastatic lesions in recurrent fallopian tube carcinoma Gynecol Oncol 87 2002 323 326
98. B.L. van Leeuwen, J. Pruim, A.S. Gouw Liver metastasis as a first sign of fallopian tube carcinoma and the role of positron emission tomography in preoperative diagnosis Scand J Gastroeneterol 37 2002 1473 1474
99. S. Beaulieu, L. Boucher, M. Lecompte Fluorine-18 fluorodeoxyglucose positron emission tomography correlated with computed tomographic scan and magnetic resonance imaging in a case of hematometrocolpos Clin Nucl Med 25 2000 486 487
100. S.A. Sohaib, E.C. Moskovic Imaging in vulval cancer Best Prac Res Clin Obstet Gynecol 17 2003 543 556
101. C.H. Kao Detecting vulvar cancer with inguinal lymph node metastases by dual-phase Tl-201 scan Clin Nucl Med 28 2003 80
102. D.E. Cohn, F. Dehdashti, R.K. Gibb Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer Gynecol Oncol 85 2002 179 184
103. I.N. Frank, S.D. Graham Jr, W.L. Nabors Urologic and male genital cancers A.I. Holleb D.J. Fink G.P. Murphy Clinical Oncology 1991 American Cancer Society Atlanta, GA 271 289
104. A.J. Lawton, G.M. Mead Staging and prognostic factors in testicular cancer Semin Surg Oncol 17 1999 223 229
105. J.T. Hartmann, H.J. Schmoll, M.A. Kuczyk Postchemotherapy resections of residual masses from metastatic nonseminomatous testicular germ cell tumors Ann Oncol 8 1997 531 538
106. N. Pandit-Taskar, A. Sinha, M. Gonen Testicular uptake in 18FDG PET scan J Nucl Med 5 suppl 2003 143P
107. M. Yun, S. Jang, W. Kim Pattern of testicular uptake with age and the effect of chemotherapy on testicular uptake determined by FDG PET J Nucl Med 5 suppl 2001 287P
108. R.A. Huddart Use of FDG-PET in testicular tumors Clin Oncol (R Coll Radiol) 15 2003 123 127
109. G. Wolf, R.M. Aigner, T. Schwarz Diagnosis of a contralateral second testicular carcinoma by F18-FDG PET Onkologie 26 2003 155 157
110. M.J. Reinhardt, A. Matthies, H.J. Biersack PET-imaging in tumors of the reproductive tract Q J Nucl Med 46 2002 105 112
111. P. Albers, H. Bender, H. Yilmaz Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumors Urology 53 1999 808 811
112. S.F. Hain, M.J. O'Doherty, A.R. Timothy Fluorodeoxyglucose PET in the initial staging of germ cell tumors Eur J Nucl Med 27 2000 590 594
113. U. Cremerius, J.E. Wildberger, H. Borchers Dose positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? Results of a study in 50 patients Urology 54 1999 900 904
114. U. Cremerius, P.J. Effert, G. Adam FDG PET for detection and therapy control of metastatic germ cell tumor J Nucl Med 39 1998 815 822
115. D. Sanchez, J.J. Zudaire, J.M. Fernandez 18F-fluoro-2-deoxyglucose- positron emission tomography in the evaluation of nonseminomatous germ cell tumors at relapse BJU Int 89 2002 912 916
116. U. Lassen, G. Daugaard, A. Eigtved Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumors Eur J Nucl Med Mol Imaging 2003 396 402
117. J.R. Spermon, L.F. De Geus-Oei, L.A. Kiemeney The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumors BJU Int 89 2002 549 556
118. P. Tsatalpas, B. Beuthien-Baumann, J. Kropp Diagnostic value of 18F-FDG positron emission tomography for detection and treatment control of malignant germ cell tumors Urol Int 68 2002 157 163
119. C. Bokemeyer, C. Kollmannsberger, K. Oechsle Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET Br J Cancer 86 2002 506 511
120. M. De Santis, C. Bokemeyer, A. Becherer Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma J Clin Oncol 19 2001 3740 3744
121. S.F. Hain, M.J. O'Doherty, A.R. Timothy Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumors at relapse Br J Cancer 83 2000 863 869
122. K.N. Ganjoo, R.J. Chan, M. Sharma Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma J Clin Oncol 17 1999 3457 3460
123. V. Muller-Mattheis, M. Reinhardt, C.D. Gerharz Positron emission tomography with [18F]-2-fluoro-2-deoxy-D-glucose (18FDG-PET) in diagnosis of retroperitoneal lymph node metastases of testicular tumors Urologe A 37 1998 609 620
124. H.J. Vesselle, F.D. Miraldi FDG PET of the retroperitoneum normal anatomy, variants, pathologic conditions, and strategies to avoid diagnostic pitfalls Radiographics 18 1998 805 823
125. F.M. Muggia, P.S. Conti Seminoma and sarcoidosis a cause for false positive mediastinal uptake in PET? Ann Oncol 9 1998 924
126. C.S. Karapetis, A.H. Strickland, D. Yip Use of fluorodeoxyglucose positron emission tomography scans in patients with advanced germ cell tumor following chemotherapy single-center experience with long-term follow up Intern Med J 33 2003 427 435
127. J.M. Nuutinen, S. Leskinen, I. Elomaa Detection of residual tumors in postchemotherapy testicular cancer by FDG-PET Eur J Cancer 33 1997 1234 1241
128. M.J. Reinhardt, V.G. Muller-Mattheis, C.D. Gerharz FDG-PET evaluation of retroperitoneal metastases of testicular cancer before and after chemotherapy J Nucl Med 38 1997 99 101
129. C.B. Wilson, H.E. Young, R.J. Ott Imaging metastatic testicular germ cell tumors with 18FDG positron emission tomography prospects for detection and management Eur J Nucl Med 22 1995 508 513
130. R. Tatlidil, H. Jadvar, P.S. Conti Utility of FDG-PET in the evaluation of residual or recurrent testicular carcinoma comparison to CT and serum tumor markers Radiology 217 2000 220
131. S.P. Potharaju, G.T. Smith, N.C. Hall Utility of FDG PET in management of testicular cancer and prediction of treatment response J Nucl Med 5 suppl 2002 118P
132. L.F. de Geus-Oei, J.R. Spermon, L.A. Kiemeney Chemotherapy response monitoring with 18FDG-PET in patients with high stage testicular germ cell cancer J Nucl Med 5 suppl 2003 131P
133. A. Becherer, M. De Santis, C. Bokemeyer FDG-PET as prognostic indicator for seminoma residuals An update from the SEMPET trial J Nucl Med 5 suppl 2003 174P
134. C.A. Meyer, D.J. Conces Imaging of intrathoracic metastases of nonseminomatous germ cell tumors Chest Surg Clin N Am 12 2002 717 738
135. A.C. Kole, H.J. Hoekstra, D.T. Sleijfer L-[1-carbon-11]tyrosine imaging of metastatic testicular nonseminoma germ cell tumors J Nucl Med 39 1998 1027 1029
136. B.D. Nguyen PET imaging of Sertoli cell tumor in androgen insensitivity syndrome Clin Nucl Med 28 2003 743 745
137. G.C. Ravizzini, M. Wagner, S. Borges-Neto Positron emission tomography detection of metastatic penile squamous cell carcinoma J Urol 165 2001 1633 1634